Chief Executive Officer of Somaxon Pharmaceuticals, Inc. (SOMX) Discusses Commercialization Strategy for Silenor® to Treat Insomnia
Somaxon Pharmaceuticals, Inc. (NASD: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, recently announced that the company’s president and chief executive officer, Richard Pascoe, presented earlier this week at the Natixis Bleichroeder second annual Hidden Gems Conference in New York, NY. At the conference, Mr. Pascoe stated that Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, Silenor® (doxepin HCl) for the treatment of insomnia. In each of these clinical trials, Silenor® demonstrated statistically…